» Articles » PMID: 22696338

Antifungal Therapy for Newborn Infants with Invasive Fungal Infection

Overview
Publisher Wiley
Date 2012 Jun 15
PMID 22696338
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A variety of antifungal drugs, drug preparations and drug combinations are available to treat newborn infants with suspected or confirmed invasive fungal infection. There is a need to assess their relative merits.

Objectives: To assess the effect of treatment with different antifungal drugs, drug preparations or drug combinations on mortality and morbidity in newborn infants with suspected or confirmed invasive fungal infection.

Search Methods: We used the standard search strategy of the Cochrane Neonatal Review Group. This included searches of the Cochrane Central Register of Controlled Trials (The Cochrane Library, 2012, Issue 2), MEDLINE, EMBASE, CINAHL (to March 2012), conference proceedings and previous reviews.

Selection Criteria: Randomised and quasi-randomised control trials comparing one antifungal agent or combination of agents with another in newborn infants with suspected or confirmed invasive fungal infection.

Data Collection And Analysis: We extracted the data using the standard methods of the Cochrane Neonatal Review Group, with separate evaluation of trial quality and data extraction by each author, and synthesis of data using risk ratio and risk difference.

Main Results: We identified only one small trial in which 24 newborn infants participated. This trial compared the use of fluconazole versus amphotericin B (plus 5-fluorocytosine if fungal meningitis present). The trial did not detect a statistically significant effect on mortality (risk ratio 0.73; 95% confidence interval 0.26 to 2.05).

Authors' Conclusions: There are insufficient data to inform practice. Large randomised controlled trials are required to compare antifungal drugs, drug preparations or drug combinations for treating newborn infants with invasive fungal infection.

Citing Articles

Review of Fluconazole Treatment and Prophylaxis for Invasive Candidiasis in Neonates.

Hornik C, Bondi D, Greene N, Cober M, John B J Pediatr Pharmacol Ther. 2021; 26(2):115-122.

PMID: 33603574 PMC: 7887891. DOI: 10.5863/1551-6776-26.2.115.


Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives.

Bersani I, Piersigilli F, Goffredo B, Santisi A, Cairoli S, Ronchetti M Front Pediatr. 2019; 7:375.

PMID: 31616647 PMC: 6764087. DOI: 10.3389/fped.2019.00375.


Clinical features and antimicrobial susceptibility profiles of culture-proven neonatal sepsis in a tertiary children's hospital, 2013 to 2017.

Li X, Ding X, Shi P, Zhu Y, Huang Y, Li Q Medicine (Baltimore). 2019; 98(12):e14686.

PMID: 30896617 PMC: 6709008. DOI: 10.1097/MD.0000000000014686.


Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations.

Andrew E, Curtis N, Coghlan B, Cranswick N, Gwee A Br J Clin Pharmacol. 2018; 84(5):1006-1012.

PMID: 29352486 PMC: 5903243. DOI: 10.1111/bcp.13521.


Invasive fungal infections in infants-focus on anidulafungin.

Wilke M Clin Med Insights Pediatr. 2013; 7:7-11.

PMID: 23641173 PMC: 3620775. DOI: 10.4137/CMPed.S8028.

References
1.
Hill H, Mitchell T, Matsen J, Quie P . Recovery from disseminated candidiasis in a premature neonate. Pediatrics. 1974; 53(5):748-52. View

2.
Tuck S . Neonatal systemic candidiasis treated miconazole. Arch Dis Child. 1980; 55(11):903-6. PMC: 1626953. DOI: 10.1136/adc.55.11.903. View

3.
Kuse E, Chetchotisakd P, da Cunha C, Ruhnke M, Barrios C, Raghunadharao D . Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007; 369(9572):1519-1527. DOI: 10.1016/S0140-6736(07)60605-9. View

4.
Gussenhoven M, Haak A, van t Wout J . Stevens-Johnson syndrome after fluconazole. Lancet. 1991; 338(8759):120. DOI: 10.1016/0140-6736(91)90112-3. View

5.
Sucher A, Chahine E, Balcer H . Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009; 43(10):1647-57. DOI: 10.1345/aph.1M237. View